OTC Stock News

[Robertscott]

$RSCZF Ground breaking research by the company's founders has led to the discovery of an endogenous molecule that primes the body's own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury.

\

The global stem cells market was worth $5.17 billion in 2017 and is projected to grow to $9.03 billion by 2023. Stem cell therapy has become the standard of care for many blood disorders, but cellular therapy for solid organs has not yet yielded the anticipated benefits.

Prof. Nanchahal's work on complex fractures has led to the identification of a highly conserved physiological pathway whereby a protein released by damaged cells accelerates repair and regeneration of multiple tissues.

Administration of only a single dose of the protein is effective across a range of disorders by targeting the body's own stem cells.

Administration of this protein to mice with injuries has been shown to speed up the healing of bone fractures, restoration of blood formation in bone marrow after chemotherapy, and repair of damaged skeletal muscle.

This is a disruptive technology which will deliver a first in class therapeutic!